About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
  FY 2016 - 2017
  
  April 2017
  March 2017
  February 2017
  January 2017
  December 2016
  November 2016
  October 2016
  September 2016
  August 2016
  July 2016
  June 2016
  May 2016
  April 2016
     
 
Disclosure to Stock Exchange

  February 2017
27 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
24 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
22 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
16 Feb  USFDA accepts Biologics License Application  (BLA) for Mylan and Biocon's proposed  Biosimilar Pegfilgrastim for Review Download Pdf
14 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
07 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf




 
     
 March 2016
 February 2016
 January 2016
 December 2015
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved